新医学Issue(5)：297-299,3.DOI:10.3969/g.issn.0253-9802.2014.05.005
重组人IL-11衍生物及重组人IL-11对恶性肿瘤化学治疗后血小板减少的临床研究
Clinical study of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombo-cytopenia in patients with malignant tumor
摘要
Abstract
Objective To evaluate the efficacy and side effect of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. Methods A total of 63 malignant tumor patients with grade Ⅲ-Ⅳ thrombocytopenia (≤50 ×1 09/L)after chemotherapy were collected and divided into treatment group and control group. At 24-48 hours after chemotherapy,the patients in treatment group received rhIL-11 derivatives 1.5 mg per day,while the patients in control group receive-drhIL-11 3 mg per day. The treatment would be ended when the platelets rose up to 1 00 ×1 09/L. The treat-ment time taken to get platelet rise up to 75 ×1 09/L or 1 00 ×1 09/L was compared between two groups. Ad-verse effects were observed during the treatment. Results There was a significant difference in the treatment time used to raise platelet up to 75 ×1 09/L between the treatment group (6.46 ±2.27)days and the control group (6.46 ±2.27)days (P<0.01 ). There was also a significant difference in the treatment time used to raise platelet up to 1 00 ×1 09/L between the treatment group (9.07 ±2.45 )days and the control group (11.59 ±2.78)days (P<0.01 ). The incidences of adverse effects between two groups showed no significant difference (P>0.05 ). Conclusion Bothe rhIL-11 derivatives and rhIL-11 are effective in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. The rhIL-11 derivatives has a more rapid effect to exhibit a slight advantage over rhIL-11.关键词
重组人白细胞介素-11衍生物/重组人白细胞介素-11/化学治疗/血小板减少Key words
rhIL-11 derivatives/rhIL-11/Chemotherapy/Thrombocytopenia引用本文复制引用
唐域,石琳..重组人IL-11衍生物及重组人IL-11对恶性肿瘤化学治疗后血小板减少的临床研究[J].新医学,2014,(5):297-299,3.基金项目
辽宁省科技厅科技攻关项目 （）
